PHBI Pharmagreen Biotech Appoints Ethan Styles as Vice President of Product Research and Development
Pharmagreen Biotech (OTCQB: PHBI) announces Ethan Styles as the new Vice President of Product Research and Development, bringing valuable expertise in therapeutic plants and molecular biology. Styles, a legacy cannabis cultivator, aims to expand Pharmagreen's focus beyond cannabis into a broader range of health products. His knowledge will aid in developing nutraceutical and protein-based formulations, enhancing the company's competitive edge. CEO Peter Wojcik highlights Styles as essential for fast-tracking revenues and shareholder value, aligning with the company's vision for wellness-oriented products.
- Appointment of Ethan Styles enhances expertise in therapeutic plant and molecular biology.
- Expansion into a broader range of health products aligns with company growth strategy.
- Development of proprietary nutraceutical formulations can lead to increased revenue.
- Concerns about continuity and experience gaps in the leadership transition.
- Potential risks associated with expanding focus beyond cannabis.
CARSON CITY, NV, Sept. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Pharmagreen Biotech, Inc., (OTCQB: PHBI), (“Pharmagreen” or the “Company) is pleased to announce that Ethan Styles has joined the Pharmagreen team in the role of Vice President of Product Research and Development. Mr. Styles’ lifelong work with therapeutic plants, cannabis, medicinal plants and fungi, combined with years of personal studies in molecular biology, has provided Ethan with keen insight into the human health benefits provided by these plants.
Mr. Styles is a third generation Mendocino County, California legacy cannabis cultivator at Long Valley Farms. He employs veganic farming techniques to produce superior craft products and utilizes the same ultra-sustainable methods to grow a wide variety of medicinal plants and mushrooms. He developed the Company’s first nutraceutical formulation, a proprietary blend of fifteen ingredients from medicinal plants and mushrooms. Mr. Styles brings crucial knowledge and experience to Pharmagreen’s growing team, contributing his unique skillset to the Company’s vision of a diversified biotech organization expanding far beyond cannabis into a broad range of functional organic health products.
Mr. Styles’ knowledge of molecular cell biology through his ongoing graduate studies dovetails with many of the Company’s existing strengths. With Mr. Styles on board, Pharmagreen intends to use its in-house knowledge of veganics, organics, tissue culture (Chibafreen), good farming practices, molecular biology and genomic technologies in future production of plant and fungi biomaterial.
Utilizing the Company's expertise in plant genetics and proprietary tissue culture technologies, Pharmagreen's transgenic program uses the newest technology available to research and create nutraceuticals, protein-based formulations, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.
“My aim as V. P. of Research and Development is to simplify health and wellness and give humanity the ability to experience the best out of life. Through ancient knowledge and today's most advanced technologies, we can develop a way of life unknown to most of the population,” Mr. Styles stated. “By using multiple genomic data platforms to cross reference client-specific data against historical and current genomic patterns, we have the ability to make very direct recommendations regarding appropriate active ingredients. I look forward to leading Pharmagreen’s development of health and wellness formulations for everyone around the world.”
“It gives me great pleasure to have Mr. Styles join our corporate team. While getting to know Ethan for the last year and a half, I experienced first hand his extensive knowledge of therapeutic plants and fungi. I learned from him what really matters when it comes to personalized health and wellness. He has been the missing link we were looking for in the production of nutraceutical whole plant and fungi-based human support product development, utilizing molecular biology and genomic based sciences,” stated Peter Wojcik, CEO of Pharmagreen. “We believe, as a team, that expanding our focus beyond cannabis is the right way to achieve our goals of fast tracking revenues, returning shareholder value, and helping people achieve the wellness they seek.”
For a video interview with Ethan Styles and Peter Wojcik, please click on the link:
https://www.youtube.com/watch?v=LfiNzV5z2d8
About Long Valley Farms LLC
Long Valley Farms is a veganic farm located in the heart of California’s famed Emerald Triangle. The Company was started to further the quality of California sun grown cannabis and is currently being operated with latest technologies as a Veganic non-spray, no-till Cannabis farm. It is cultivating legacy and heritage cannabis strains for organically produced, highest quality flower tops along with other high valued pharmaceutical plant species and fungi.
About Pharmagreen Biotech, Inc.
Pharmagreen Biotech Inc. (OTCQB: PHBI) is building a vertically integrated cannabis business in the state of California. Pharmagreen utilizes its proprietary tissue culture system, called "Chibafreen", to ensure that all plants are disease- and pest-free while maintaining genetic uniformity from one generation to the next. These premium plantlets are then grown to maturity using cultivation technologies developed over three generations by grand master cultivators, on a veganic and non-spray certified farm designated by Mendocino County, California as a Legacy Status cannabis farm. Pharmagreen Biotech is committed to the cultivation and manufacture of the highest quality craft cannabis products.
Pharmagreen is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Pharmagreen's transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions. For further information on the Company, and our updated website, please visit www.pharmagreen.ca
Safe Harbor Statement
This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. In particular, factors that could cause actual results to differ materially from those in forward looking statements include: our inability to obtain additional financing on acceptable terms; risk that our products and services will not gain widespread market acceptance; inability to compete with others who provide comparable products; the failure of our technology; the infringement of our technology with proprietary rights of third parties; inability to respond to consumer demands; inability to replace significant customers; seasonal nature of our business. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. When used in this document, the words "believe," "expect," "anticipate," "estimate," "project," "plan," "should," "intend," "may," "will," "would," "potential," and similar expressions may be used to identify forward-looking statements.
The OTC Markets or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release that has been prepared by management.
Contact Information:
www.pharmagreen.ca
Tel: (702) 803 9404
Email: info@pharmagreen.ca
FAQ
Who is Ethan Styles and what is his role at Pharmagreen Biotech?
What are the expected impacts of hiring Ethan Styles on Pharmagreen's business?
What strategic direction is Pharmagreen Biotech taking with the recent management change?
